Molecular Genetics Core

项目摘要/摘要-分子遗传学核心 鉴于模式生物和分子遗传学工具在糖尿病及其相关疾病研究中的价值 病态，分子遗传学核心(MGC)旨在帮助糖尿病研究人员开发 新的啮齿动物模型和分子工具来确定参与致病的细胞和分子机制 糖尿病。MGC成立于2015年，是一个收费的服务核心，旨在促进分子的应用 遗传学方法对糖尿病相关研究的影响。具体地说，MGC(1)设计和生产的基因- 用于糖尿病相关研究的改良啮齿动物模型(使用CRISPR/Cas9)；(2)设计和生产 用于糖尿病研究的AAV载体；(3)生产和提供专业病毒试剂，用于 糖尿病研究；以及(4)向MDRC成员提供使用这些技术的建议和培训 实验室。MG Core还拥有和维护几台共享设备，供MDRC使用 成员分布在密歇根大学医学院周围的不同地点。 虽然CRISPR/Cas9技术极大地提高了速度并降低了成本 可以生成模型，这项新技术继续发展的速度可以预防许多糖尿病 研究人员无法充分利用其潜力。MGC通过利用其专业知识和 设计和构建CRISPR/Cas9靶向试剂的人员，与UM转基因核心合作 为了在胚胎中测试这些试剂，并培育出方正小鼠，并确定要移植的方正小鼠(连同 基因分型协议)提供给MDRC调查员。对于病毒试剂的产生，MGC设计并 产生任何必要的结构，这些结构由UM病毒载体核心打包成病毒。带输入 从MDRC成员和MGC咨询委员会，MGC还确定和开发新的 技术(病毒和遗传)，以支持MDRC成员的研究计划。

Project Summary/Abstract - Molecular Genetics Core Given the value of model organisms and molecular genetic tools for the study of diabetes and its co- morbidities, the Molecular Genetics Core (MGC) is designed to aid diabetes researchers in the development of novel rodent models and molecular tools to determine the cellular and molecular mechanisms contributing to diabetes. Established in 2015, the MGC is a fee-for-service core that facilitates the application of molecular genetic methods to diabetes-related research. Specifically, the MGC (1) designs and produces genetically- modified rodent models (using CRISPR/Cas9) for use in diabetes-related research; (2) designs and produces AAV vectors for use in diabetes research; (3) produces and provides specialty viral reagents for use in diabetes research; and (4) provides advice and training in the use of these technologies to members of MDRC laboratories. The MG Core also owns and maintains several pieces of shared equipment for the use of MDRC members located at different sites around the UM medical campus. While CRISPR/Cas9 technology has dramatically increased the speed and decreased the cost at which such models can be generated, the pace at which this new technology continues to evolve prevents many diabetes researchers from taking full advantage of its potential. The MGC fills this gap by using its expertise and personnel to design and construct CRISPR/Cas9 targeting reagents, collaborate with the UM Transgenic Core to test these reagents in embryos and produce founder mice, and identify founders for transfer (along with genotyping protocols) to the MDRC investigator. For the generation of viral reagents, the MGC designs and produces any necessary constructs, which are packaged into viruses by the UM Viral Vector Core. With input from MDRC members and the MGC advisory committee, the MGC also identifies and develops new technologies (viral and genetic) in support of the research programs of MDRC members.